1-17 of 17
Sridhar Mani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Patricia M. LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen I. Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2954–2963.
https://doi.org/10.1158/1078-0432.CCR-11-2873
Published: 14 May 2012
View article titled, Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Open the PDF for Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 in another window
Journal Articles

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4207–4212.
https://doi.org/10.1158/1078-0432.CCR-08-2429
Published: 15 June 2009
View article titled, A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7110–7115.
https://doi.org/10.1158/1078-0432.CCR-08-0483
Published: 03 November 2008
View article titled, A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Open the PDF for A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies in another window
Journal Articles

Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer

Divya Gupta, Madhukumar Venkatesh, Hongwei Wang, Sean Kim, Michael Sinz, Gary L. Goldberg, Kathleen Whitney, Clifford Longley, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5332–5340.
https://doi.org/10.1158/1078-0432.CCR-08-1033
Published: 02 September 2008
View article titled, Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer
Open the PDF for Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer in another window
Journal Articles

The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Sanjay Goel, Marvin Cohen, S. Nilgün Çömezoglu, Lionel Perrin, François André, David Jayabalan, Lisa Iacono, Adriana Comprelli, Van T. Ly, Donglu Zhang, Carrie Xu, W. Griffith Humphreys, Hayley McDaid, Gary Goldberg, Susan B. Horwitz, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2701–2709.
https://doi.org/10.1158/1078-0432.CCR-07-4151
Published: 01 May 2008
View article titled, The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Open the PDF for The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development in another window
Includes: Supplementary data
Journal Articles

Rhabdoid Tumor Growth is Inhibited by Flavopiridol

Melissa E. Smith, Velasco Cimica, Srinivasa Chinni, Kavitha Challagulla, Sridhar Mani, Ganjam V. Kalpana
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 523–532.
https://doi.org/10.1158/1078-0432.CCR-07-1347
Published: 25 January 2008
View article titled, Rhabdoid Tumor Growth is Inhibited by Flavopiridol
Open the PDF for Rhabdoid Tumor Growth is Inhibited by Flavopiridol in another window
Journal Articles

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

Chris H. Takimoto, Martin A. Graham, Graham Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel L. Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4832–4839.
https://doi.org/10.1158/1078-0432.CCR-07-0475
Published: 15 August 2007
View article titled, Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function
Open the PDF for Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function in another window
Journal Articles

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

Timothy W. Synold, Chris H. Takimoto, James H. Doroshow, David Gandara, Sridhar Mani, Scot C. Remick, Daniel L. Mulkerin, Anne Hamilton, Sunil Sharma, Ramesh K. Ramanathan, Heinz Josef Lenz, Martin Graham, Jeffrey Longmate, Bennett M. Kaufman, Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3660–3666.
https://doi.org/10.1158/1078-0432.CCR-06-2385
Published: 15 June 2007
View article titled, Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs

Hongwei Wang, Haiyan Huang, Hao Li, Denise G. Teotico, Michael Sinz, Sharyn D. Baker, Jeffrey Staudinger, Ganjam Kalpana, Matthew R. Redinbo, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (8): 2488–2495.
https://doi.org/10.1158/1078-0432.CCR-06-1592
Published: 16 April 2007
View article titled, Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs
Open the PDF for Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs in another window
Journal Articles

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1246–1252.
https://doi.org/10.1158/1078-0432.CCR-06-1096
Published: 22 February 2007
View article titled, Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs
Open the PDF for Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs in another window
Journal Articles

Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents

Sridhar Mani, Haiyan Huang, Sumathy Sundarababu, Wenjing Liu, Ganjam Kalpana, Amos B. Smith, Susan B. Horwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6359–6369.
https://doi.org/10.1158/1078-0432.CCR-05-0252
Published: 06 September 2005
View article titled, Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents
Open the PDF for Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

Sridhar Mani, Hayley McDaid, Anne Hamilton, Howard Hochster, Marvin B. Cohen, Dineo Khabelle, Tom Griffin, David E. Lebwohl, Leonard Liebes, Franco Muggia, Susan Band Horwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (4): 1289–1298.
https://doi.org/10.1158/1078-0432.CCR-0919-03
Published: 20 February 2004
View article titled, Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors
Open the PDF for Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors in another window
Journal Articles

A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors

Sanjay Goel, Kavita Desai, Anca Bulgaru, Abbie Fields, Gary Goldberg, Sudhir Agrawal, Russell Martin, Michael Grindel, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4069–4076.
Published: 30 September 2003
View article titled, A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors
Open the PDF for A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors in another window
Journal Articles

Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, during a Phase I Clinical Study

Hayley M. McDaid, Sridhar Mani, Heng-Jia Shen, Franco Muggia, Daryl Sonnichsen, Susan Band Horwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2035–2043.
Published: 01 July 2002
View article titled, Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, during a Phase I Clinical Study
Open the PDF for Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, during a Phase I Clinical Study in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Sridhar Mani, Charles M. Rudin, Katie Kunkel, Jon T. Holmlund, Richard S. Geary, Hedy L. Kindler, F. Andrew Dorr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1042–1048.
Published: 01 April 2002
View article titled, Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer in another window
Journal Articles

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer

Charles M. Rudin, Jon Holmlund, Gini F. Fleming, Sridhar Mani, Walter M. Stadler, Philip Schumm, Brett P. Monia, Joseph F. Johnston, Richard Geary, Rosie Z. Yu, T. Jesse Kwoh, F. Andrew Dorr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1214–1220.
Published: 01 May 2001
View article titled, Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-<em>raf</em>-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer
Open the PDF for Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-<em>raf</em>-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer in another window
Journal Articles

Phase I Clinical and Pharmacological Study of O6-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer

Richard L. Schilsky, M. Eileen Dolan, Donna Bertucci, Reginald B. Ewesuedo, Nicholas J. Vogelzang, Sridhar Mani, Lynette R. Wilson, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (8): 3025–3031.
Published: 01 August 2000
View article titled, Phase I Clinical and Pharmacological Study of <em>O</em><sup>6</sup>-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacological Study of <em>O</em><sup>6</sup>-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer in another window